Latest Fund Strategy News

Macquarie Bank Limited reported an 18% rise in net profit for FY2025, driven by growth in its retail banking segment despite margin pressures, while its commodities business faced subdued markets. The bank maintained strong capital ratios and advanced its risk and technology frameworks amid regulatory scrutiny.

Tivan Limited has locked in a $5 million share placement and signed a non-binding term sheet for a $51.3 million equity investment to fund the Speewah Fluorite Project, marking a significant step in its development plans.

NEXTDC reports a significant 30% jump in contracted utilisation to 228MW, driven by strong AI deployments in Victoria, prompting a $100 million increase in FY25 capital expenditure guidance.

A shareholder has lodged an application with the Takeovers Panel challenging FBR Limited’s upcoming extraordinary general meeting resolutions related to significant share placements and funding arrangements with Fidelity International.

Papyrus Australia has issued a revised Appendix 4C for the March 2025 quarter, correcting the treatment of $527k in R&D expenditure previously reported as cash payments. This adjustment also impacts prior monthly and quarterly cash flow reports dating back to November 2024.

Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.

Resolute Mining has acquired AngloGold Ashanti’s Doropo and ABC gold projects in Côte d’Ivoire for US$150 million plus contingent payments, significantly boosting its resource base and positioning for production growth beyond 500,000 ounces annually by 2030.

Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.

Challenger Gold Limited reported a net cash outflow in operating and investing activities for Q1 2025 but bolstered liquidity through a significant financing drawdown tied to its milling project.

Admiralty Resources NL reported a modest operating cash inflow of A$398,000 for Q1 2025, offset by significant investing outflows tied to the Mariposa project. The company maintains a solid cash position supported by existing loan facilities maturing at year-end.